| [1] Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme W, Qaddoumi I, Surrey LF, Li MM, Waanders AJ, Gilheeney S, Rosenblum M, Bale T, Tsang DS, Laperriere N, Kulkarni A, Ibrahim GM, Drake J, Dirks P, Taylor MD, Rutka JT, Laughlin S, Shroff M, Shago M, Hazrati LN, D'rcy C, Ramaswamy V, Bartels U, Huang A, Bouffet E, Karajannis MA, Santi M, Ellison DW, Tabori U, Hawkins C. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas[J]. Cancer Cell, 2020, 37:569-583.
[2] Yang RR, Aibaidula A, Wang WW, Chan AK, Shi ZF, Zhang ZY, Chan DTM, Poon WS, Liu XZ, Li WC, Zhang RQ, Li YX, Chung NY, Chen H, Wu J, Zhou L, Li KK, Ng HK. Pediatric low-grade gliomas can be molecularly stratified for risk[J]. Acta Neuropathol, 2018, 136:641-655.
[3] Bag AK, Chiang J, Patay Z. Radiohistogenomics of pediatric low-grade neuroepithelial tumors[J]. Neuroradiology, 2021, 63:1185-1213.
[4] Ampie L, Choy W, DiDomenico JD, Lamano JB, Williams CK, Kesavabhotla K, Mao Q, Bloch O. Clinical attributes and surgical outcomes of angiocentric gliomas[J]. J Clin Neurosci, 2016, 28:117-122.
[5] Han G, Zhang J, Ma Y, Gui Q, Yin S. Clinical characteristics, treatment and prognosis of angiocentric glioma[J]. Oncol Lett, 2020, 20:1641-1648.
[6] Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D, Karajannis MA, Benayed R, Chavez L, Thomas C, Serrano J, Borsu L, Ladanyi M, Rosenblum MK. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY):an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway[J]. Acta Neuropathol, 2017, 133:417-429.
[7] Gupta VR, Giller C, Kolhe R, Forseen SE, Sharma S. Polymorphous low-grade neuroepithelial tumor of the young:a case report with genomic findings[J]. World Neurosurg, 2019, 132:347-355.
[8] Benson JC, Summerfield D, Carr C, Cogswell P, Messina S, Gompel JV, Welker K. Polymorphous low-grade neuroepithelial tumor of the young as a partially calcified intra-axial mass in an adult[J]. AJNR Am J Neuroradiol, 2020, 41:573-538.
[9] Chen Y, Tian T, Guo X, Zhang F, Fan M, Jin H, Liu D. Polymorphous low-grade neuroepithelial tumor of the young:case report and review focus on the radiological features and genetic alterations[J]. BMC Neurol, 2020, 20:123.
[10] Bitar M, Danish SF, Rosenblum MK. A newly diagnosed case of polymorphous low-grade neuroepithelial tumor of the young[J]. Clin Neuropathol, 2018, 37:178-181.
[11] Behling F, Barrantes-Freer A, Skardelly M, Nieser M, Christians A, Stockhammer F, Rohde V, Tatagiba M, Hartmann C, Stadelmann C, Schittenhelm J. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms[J]. Diagn Pathol, 2016, 11:55.
[12] Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A, Rabadan R, Iavarone A. Transforming fusions of FGFR and TACC genes in human glioblastoma[J]. Science, 2012, 337:1231-1235.
[13] Tateishi K, Ikegaya N, Udaka N, Sasame J, Hayashi T, Miyake Y, Okabe T, Minamimoto R, Murata H, Utsunomiya D, Yamanaka S, Yamamoto T. BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young[J]. Acta Neuropathol Commun, 2020, 8:139.
[14] Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, Louis DN. cIMPACT-NOW update 4:diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation[J]. Acta Neuropathol, 2019, 137:683-687.
[15] Fukuoka K, Mamatjan Y, Ryall S, Komosa M, Bennett J, Zapotocky M, Keith J, Myrehaug S, Hazrati LN, Aldape K, Laperriere N, Bouffet E, Tabori U, Hawkins C. BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults[J]. Brain Pathol, 2020, 30:515-523.
[16] Ho CY, Mobley BC, Gordis-Dressman H, VandenBussche CJ, Mason GE, Bornhorst M, Esbenshade AJ, Tehrani M, Orr BA, LaFrance DR, Devaney JM, Meltzer BW, Hofherr SE, Burger PC, Packer RJ, Rodriguez FJ. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation[J]. Acta Neuropathol, 2015, 130:575-585.
[17] Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Nageswara Rao A, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Faure Conter C, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, Tabori U. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas[J]. J Clin Oncol, 2017, 35:2934-2941.
[18] Wang SS, Bandopadhayay P, Jenkins MR. Towards immunotherapy for pediatric brain tumors[J]. Trends Immunol, 2019, 40:748-761.
[19] Zhang L, Zhang B, Dou Z, Wu J, Iranmanesh Y, Jiang B, Sun C, Zhang J. Immune checkpoint-associated locations of diffuse gliomas comparing pediatric with adult patients based on voxel-wise analysis[J]. Front Immunol, 2021, 12:582594.
[20] Kelly WJ, Giles AJ, Gilbert M. T lymphocyte-targeted immune checkpoint modulation in glioma[J]. J Immunother Cancer, 2020, 8:e000379.
[21] Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P. cIMPACT-NOW update 2:diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant[J]. Acta Neuropathol, 2018, 135:639-642.
[22] Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Targeting and therapeutic monitoring of H3K27M-mutant glioma[J]. Curr Oncol Rep, 2020, 22:19.
[23] Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M + diffuse midline gliomas[J]. Nat Med, 2018, 24:572-579.
[24] Piccardo A, Tortora D, Mascelli S, Severino M, Piatelli G, Consales A, Pescetto M, Biassoni V, Schiavello E, Massollo M, Verrico A, Milanaccio C, Garrè ML, Rossi A, Morana G. Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas[J]. Eur J Nucl Med Mol Imaging, 2019, 46:1685-1694.
[25] Szychot E, Youssef A, Ganeshan B, Endozo R, Hyare H, Gains J, Mankad K, Shankar A. Predicting outcome in childhood diffuse midline gliomas using magnetic resonance imaging based texture analysis[J]. J Neuroradiol, 2021, 48:243-247.
[26] Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S, Cha S. Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation[J]. AJNR Am J Neuroradiol, 2017, 38:795-800.
[27] Thust S, Micallef C, Okuchi S, Brandner S, Kumar A, Mankad K, Wastling S, Mancini L, Jäger HR, Shankar A. Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults[J]. Quant Imaging Med Surg, 2021, 11:43-56.
[28] Castel D, Kergrohen T, Tauziède-Espariat A, Mackay A, Ghermaoui S, Lechapt E, Pfister SM, Kramm CM, Boddaert N, Blauwblomme T, Puget S, Beccaria K, Jones C, Jones DTW, Varlet P, Grill J, Debily MA. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation[J]. Acta Neuropathol, 2020, 139:1109-1113.
[29] Jain SU, Rashoff AQ, Krabbenhoft SD, Hoelper D, Do TJ, Gibson TJ, Lundgren SM, Bondra ER, Deshmukh S, Harutyunyan AS, Juretic N, Jabado N, Harrison MM, Lewis PW. H3 K27M and EZHIP impede H3K27-methylation spreading by inhibiting allosterically stimulated PRC2[J]. Mol Cell, 2020, 80:726-735.
[30] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System:a summary[J]. Neuro Oncol, 2021, 23:1231-1251.
[31] Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression:a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group[J]. Eur J Cancer, 2017, 73:38-47.
[32] Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park SH, Paulus W, Perry A, Pietsch T, Reifenberger G, Rosenblum M, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, Weller M, White VA, Ellison DW. cIMPACT-NOW update 6:new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading[J]. Brain Pathol, 2020, 30:844-856.
[33] Korshunov A, Capper D, Reuss D, Schrimpf D, Ryzhova M, Hovestadt V, Sturm D, Meyer J, Jones C, Zheludkova O, Kumirova E, Golanov A, Kool M, Schüller U, Mittelbronn M, Hasselblatt M, Schittenhelm J, Reifenberger G, Herold-ende C, Lichter P, von Deimling A, Pfister SM, Jones DT. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity[J]. Acta Neuropathol, 2016, 131:137-146.
[34] Onishi S, Amatya VJ, Karlowee V, Takeshima Y, Sugiyama K, Kurisu K, Yamasaki F. Radiological and immunostaining characteristics of H3.3 G34R-mutant glioma:a report of 3 cases and review of the literature[J]. Pediatr Neurosurg, 2020, 55:319-325.
[35] Lim KY, Won JK, Park CK, Kim SK, Choi SH, Kim T, Yun H, Park SH. H3 G34-mutant high-grade glioma[J]. Brain Tumor Pathol, 2021, 38:4-13.
[36] Picart T, Barritault M, Poncet D, Berner LP, Izquierdo C, Tabouret E, Figarella-Branger D, Idbaïh A, Bielle F, Bourg V, Vandenbos FB, Moyal EC, Uro-Coste E, Guyotat J, Honnorat J, Gabut M, Meyronet D, Ducray F. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults[J]. Neurooncol Adv, 2021, 3:vdab061.
[37] Korshunov A, Schrimpf D, Ryzhova M, Sturm D, Chavez L, Hovestadt V, Sharma T, Habel A, Burford A, Jones C, Zheludkova O, Kumirova E, Kramm CM, Golanov A, Capper D, von Deimling A, Pfister SM, Jones DTW. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers[J]. Acta Neuropathol, 2017, 134:507-516.
[38] Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma:close relatives or distant cousins[J]? Nat Rev Clin Oncol, 2012, 9:400-413.
[39] Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, Bridge T, Kim B, Arnoldo A, Kowalski PE, Zhong Y, Johnson M, Li C, Ramani AK, Siddaway R, Nobre LF, de Antonellis P, Dunham C, Cheng S, Boué DR, Finlay JL, Coven SL, de Prada I, Perez-Somarriba M, Faria CC, Grotzer MA, Rushing E, Sumerauer D, Zamecnik J, Krskova L, Garcia Ariza M, Cruz O, Morales La Madrid A, Solano P, Terashima K, Nakano Y, Ichimura K, Nagane M, Sakamoto H, Gil-da-Costa MJ, Silva R, Johnston DL, Michaud J, Wilson B, van Landeghem FKH, Oviedo A, McNeely PD, Crooks B, Fried I, Zhukova N, Hansford JR, Nageswararao A, Garzia L, Shago M, Brudno M, Irwin MS, Bartels U, Ramaswamy V, Bouffet E, Taylor MD, Tabori U, Hawkins C. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas[J]. Nat Commun, 2019, 10:4343.
[40] Ng A, Levy ML, Malicki DM, Crawford JR. Unusual high-grade and low-grade glioma in an infant with PPP1CB-ALK gene fusion[J]. BMJ Case Rep, 2019, 12:e228248.
[41] Haberler C, Slavc I, Czech T, Prayer D, Pirker C, Budka H, Hainfellner JA. Malignant predominantly minigemistocytic glioma in two infants:a distinctive glioma variant[J]? Neuropathol Appl Neurobiol, 2007, 33:169-178.
[42] Macy ME, Birks DK, Barton VN, Chan MH, Donson AM, Kleinschmidt-Demasters BK, Bemis LT, Handler MH, Foreman NK. Clinical and molecular characteristics of congenital glioblastoma[J]. Neuro Oncol, 2012, 14:931-941.
[43] Takeshima H, Kawahara Y, Hirano H, Obara S, Niiro M, Kuratsu J. Postoperative regression of desmoplastic infantile gangliogliomas:report of two cases[J]. Neurosurgery, 2003, 53:979-983. |